Targeting PRC1 in leukemia
靶向 PRC1 治疗白血病
基本信息
- 批准号:10712963
- 负责人:
- 金额:$ 62.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2028-08-31
- 项目状态:未结题
- 来源:
- 关键词:Acute Myelocytic LeukemiaAcute leukemiaAffinityAnimal ModelBMI1 geneBindingBiologyBlood CellsBone Marrow CellsCell LineCellsChemicalsChromatinComplexDepositionDevelopmentDiseaseDrug KineticsEpigenetic ProcessGenerationsGoalsHOXA9 geneHematopoiesisHistone H2AHydrolysisLeukemic CellMaintenanceModelingMolecular AbnormalityMonoubiquitinationMusNamesNucleosomesOncogenesOutcomePRC1 ProteinPatientsPermeabilityPharmaceutical ChemistryPharmaceutical PreparationsProdrugsPropertyProteinsRecurrenceResearchResistanceSamplingSolubilityStem Cell ResearchStructureTestingTherapeuticTherapeutic AgentsToxic effectUbiquitinationUndifferentiatedWorkXenograft Modelacute leukemia cellacute myeloid leukemia cellanaloganti-cancer therapeuticantileukemic agentcell growthchemotherapyclinical applicationdesignefficacy studyimprovedin vivoinhibitorinnovationinterdisciplinary approachleukemialeukemic stem cellleukemogenesismouse modelnovelnovel anticancer drugnovel strategiesnovel therapeutic interventionoverexpressionparalogous genepatient derived xenograft modelpharmacologicscreeningself-renewalsmall moleculesmall molecule inhibitorstem cellsstructural biologytargeted treatmentubiquitin-protein ligase
项目摘要
Abstract
Acute leukemia is an aggressive disease resulting from various genetic abnormalities and is characterized by
the presence of undifferentiated blood cells. Emerging evidence shows that recurrence of acute leukemia
results from the activity of leukemic stem cells (LSCs), which are resistant to chemotherapy, supporting the
need for new pharmacological agents inducing differentiation of LSCs. The self-renewal and differentiation
capacity of stem cells, including LSCs, are dependent on the activity of the Polycomb repressive complex 1
(PRC1). The core of all PRC1 complexes comprises heterodimeric complexes involving RING1B or RING1A
and one of the PCGF1-6 paralogs, which catalyze monubiquitination of histone H2A (H2Aub) constituting a
strong repressive mark. Simultaneous depletion of core PRC1 components RING1A/B results in a loss of
H2Aub deposition, cell growth arrest and differentiation of acute leukemia cells driven by the oncogenes
associated with expression of HOXA9. Therefore, blocking PRC1 activity with small molecules could lead to
eradication of LSCs and differentiation of leukemic blasts.
The major goal of this project is to develop potent small molecule inhibitors blocking the activity of PRC1 by a
direct inhibition of the RING1B-BMI1 E3 ubiquitin ligase to induce differentiation of leukemic cells. To this end,
we employed fragment-based screening followed by extensive medicinal chemistry to develop the first-in-class
small molecules that directly bind to the RING1A/B proteins and inhibit PRC1 activity through blocking the
interaction of the PRC1 complex with nucleosomes. Our first-generation inhibitor RB-3 decreases global level
of H2Aub and induces differentiation in leukemia cells and primary AML samples. The goal of this proposal is
to optimize this class of compounds and develop potent PRC1 inhibitors with optimized drug-like properties
and pronounced in vivo efficacy in animal models of acute leukemia. We will employ extensive medicinal
chemistry and structure-based design approach to optimize PRC1 inhibitors. All inhibitors will be characterized
to determine binding affinity, inhibitory activity, and cellular activity to inhibit H2Aub. Best compounds will be
extensively evaluated in a panel of leukemia cell lines. We will assess the mechanism of action of the PRC1
inhibitors and test their activity in the models of LSCs and in the primary AML patient samples. The optimized
compounds will be assessed in vivo for their potential to block development of leukemia in mouse models of
AML. Our studies will explore a new approach to induce differentiation of leukemia cells and LSCs and may
lead to the development of highly valuable chemical probe compounds or novel pharmacologic agents for
acute leukemia patients.
摘要
急性白血病是一种由各种基因异常引起的侵袭性疾病,其特点是
存在未分化的血细胞。越来越多的证据表明,急性白血病复发
从白血病干细胞(LSCs)的活性来看,这种细胞对化疗具有抗药性,支持
需要新的药物诱导LSCs分化。自我更新与差异化
干细胞的能力,包括LSCs,取决于多梳抑制复合体1的活性
(PRC1)。所有PrC1络合物的核心都是含有Ring1b或Ring1a的异二聚体络合物
和PCGF1-6类似物之一,它催化组蛋白H_2A(H_2Aub)的单泛素化,构成
强烈的压抑痕迹。核心PRC1组件RING1A/B的同时耗尽导致损失
癌基因对急性白血病细胞H_2Aub沉积、细胞生长停滞和分化的影响
与HOXA9的表达相关。因此,用小分子阻断Prc1活性可能导致
LSCs的根除和白血病原始细胞的分化。
该项目的主要目标是开发有效的小分子抑制剂,通过一种有效的方法阻断Prc1的活性。
直接抑制Ring1b-BMI1 E3泛素连接酶诱导白血病细胞分化。为此,
我们使用了基于片段的筛选和广泛的药物化学来开发一流的
直接与RING1A/B蛋白结合并通过阻断RING1A/B蛋白抑制PRC1活性的小分子
Prc1复合体与核小体的相互作用。我们的第一代抑制剂RB-3降低了全球水平
并在白血病细胞和原代AML样本中诱导分化。这项提议的目标是
优化这类化合物并开发具有优化类药物性能的有效PRC1抑制剂
并在急性白血病动物模型中表现出显著的体内疗效。我们将广泛使用医疗设备
基于化学和结构的设计方法来优化Prc1抑制剂。所有的抑制剂都将被表征
测定结合亲和力、抑制活性和细胞活性以抑制H_2Aub。最好的化合物将是
在一组白血病细胞系中进行了广泛的评估。我们将评估革命制度改革委员会的行动机制。
并在LSCs模型和原发AML患者样本中测试它们的活性。经过优化的
将在体内评估化合物在小鼠模型中阻止白血病发展的潜力。
AML。我们的研究将探索一种新的方法来诱导白血病细胞和LSCs分化,并可能
导致开发高价值的化学探针化合物或新的药理试剂
急性白血病患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tomasz Cierpicki其他文献
Tomasz Cierpicki的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tomasz Cierpicki', 18)}}的其他基金
Development of small molecules targeting Ring1B-Bmi1 E3 ligase in leukemia
开发针对白血病的 Ring1B-Bmi1 E3 连接酶的小分子
- 批准号:
9153143 - 财政年份:2016
- 资助金额:
$ 62.5万 - 项目类别:
Inhibition of CDC25B phosphatase by targeting protein-protein interactions
通过靶向蛋白质-蛋白质相互作用抑制 CDC25B 磷酸酶
- 批准号:
8611254 - 财政年份:2013
- 资助金额:
$ 62.5万 - 项目类别:
相似海外基金
Targeting Menin in Acute Leukemia with Upregulated HOX Genes
通过上调 HOX 基因靶向急性白血病中的 Menin
- 批准号:
10655162 - 财政年份:2023
- 资助金额:
$ 62.5万 - 项目类别:
Rapid Acute Leukemia Genomic Profiling with CRISPR enrichment and Real-time long-read sequencing
利用 CRISPR 富集和实时长读长测序进行快速急性白血病基因组分析
- 批准号:
10839678 - 财政年份:2023
- 资助金额:
$ 62.5万 - 项目类别:
Rapid Acute Leukemia Genomic Profiling with CRISPR enrichment and Real-time long-read sequencing
利用 CRISPR 富集和实时长读长测序进行快速急性白血病基因组分析
- 批准号:
10651543 - 财政年份:2023
- 资助金额:
$ 62.5万 - 项目类别:
Experimental and preclinical modeling of NUP98-rearranged acute leukemia
NUP98重排急性白血病的实验和临床前模型
- 批准号:
10829603 - 财政年份:2023
- 资助金额:
$ 62.5万 - 项目类别:
A Systems Epidemiology Approach for Predicting Methotrexate Neurotoxicity in Pediatric Acute Leukemia
预测儿童急性白血病甲氨蝶呤神经毒性的系统流行病学方法
- 批准号:
10655716 - 财政年份:2023
- 资助金额:
$ 62.5万 - 项目类别:
Anti-CD25 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Leukemia
抗CD25放射免疫治疗和全骨髓照射治疗复发难治性急性白血病
- 批准号:
10435886 - 财政年份:2022
- 资助金额:
$ 62.5万 - 项目类别:
mRNA stability and its impact on hematopoiesis and acute leukemia
mRNA稳定性及其对造血和急性白血病的影响
- 批准号:
10339742 - 财政年份:2022
- 资助金额:
$ 62.5万 - 项目类别:
Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention
通过多层次干预使急性白血病临床试验招募多样化
- 批准号:
10505579 - 财政年份:2022
- 资助金额:
$ 62.5万 - 项目类别:
Clonal dynamics and chemoresistance mechanisms of minimal residual disease in acute leukemia
急性白血病微小残留病的克隆动力学和化疗耐药机制
- 批准号:
10351765 - 财政年份:2022
- 资助金额:
$ 62.5万 - 项目类别:
Anti-CD25 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Leukemia
抗CD25放射免疫治疗和全骨髓照射治疗复发难治性急性白血病
- 批准号:
10576955 - 财政年份:2022
- 资助金额:
$ 62.5万 - 项目类别: